Key result
Persistent elevation of both hs-cTnT and NT-proBNP at 14 days after allogeneic hematopoietic stem cell transplantation was a strong prognostic factor for cardiac events, yielding an AUC of 0.95.
Why the study?
Allogeneic HSCT can cause organ damage, and this study aimed to assess the prognostic value of hs-cTnT and NT-proBNP testing for early identification of patients at high risk of a cardiac event after transplantation.
Do serial measurements of hs-cTnT and NT-proBNP predict early cardiac events in patients undergoing allogeneic hematopoietic stem cell transplantation?
Cohort (n=63)
No
Do serial measurements of hs-cTnT and NT-proBNP predict early cardiac events in patients undergoing allogeneic hematopoietic stem cell transplantation?
Effect estimate: AUC 0.95
p-value: p=<0.0001
Combined measurement of hs-cTnT and NT-proBNP at 14 days post-HSCT is a highly sensitive and specific prognostic tool for identifying patients at high risk of early cardiotoxicity.
hs-cTnT may flag subclinical cardiac risk post-HSCT; leaves open prospective validation before routine use.
No takes yet. Share an insight, caveat, or question.
Harvanová et al. (2022) conducted a cohort in Hematologic diseases undergoing allogeneic hematopoietic stem cell transplantation (n=63). Elevated hs-cTnT and NT-proBNP at day 14 post-transplantation vs. Normal biomarker levels was evaluated on Development of a cardiac event (arrhythmia, pericardial effusion with tamponade, or heart failure) (AUC 0.95, p=<0.0001). Persistent elevation of both hs-cTnT and NT-proBNP at 14 days after allogeneic hematopoietic stem cell transplantation was a strong prognostic factor for cardiac events, yielding an AUC of 0.95.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: